ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Gori to Return As Head Of Smoking Program; Wisconsin, AACI To Honor Harold Rusch

May 18, 1979

DCT Concepts Approved

October 11, 1985

Phase III Avastin Trial Fails Primary Endpoints

February 28, 2014

GAO Recommends Tighter Policies on NIH Recusals.

June 29, 2007

NCI Anticipates 60% Decline In Number Of New Trials By Cooperative Groups.

January 12, 2007

AACR, Kellogg’s Co. Sponsor Award

January 5, 1996